VivoSeq
Immunology

Sjogren's Syndrome

3

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Sjogren's Syndrome is an early-stage landscape with 3 programs across 4 companies. The most active players are Prism Pharmaceuticals, Johnson & Johnson, Novartis. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Tofacitinib

Prism Pharmaceuticals

Phase 32

Nipocalimab

Johnson & Johnson

Ianalumab

Novartis

Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 60% of 5 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed13 · 59%
Unknown status3 · 14%
Recruiting3 · 14%
Active, not recruiting2 · 9%
Terminated1 · 5%

Clinical Trials

Trial Activity

22 trials

Characterization of Diseases With Salivary Gland Involvement
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·N/A·NCT02327884·1,150 enrolled
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT07281456·60 enrolled
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
Recruiting·UUniversity Hospital, Brest·Preclinical·NCT04931160·1,000 enrolled
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjögren's Syndrome
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05985915·612 enrolled
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults With Moderate to Severe Sjogren's Disease (SjD)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06741969·655 enrolled
DHEA Treatment for Sjogren's Syndrome
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001598·28 enrolled
Etanercept Therapy for Sjogren's Syndrome
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001954·28 enrolled
Fecal Microbial Transplant (FMT) for Sjogrens Syndrome
Completed·UUniversity of Miami·Phase 1·NCT03926286·10 enrolled
Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome
Completed·UUniversity Hospital, Bordeaux·N/A·NCT03841318·57 enrolled
Fish Oil (Omega 3 ) in Sjogren's Syndrome
Completed·HHawler Medical University·Phase 2/3·NCT05005806·100 enrolled
CEQUA for Sjogren's Syndrome Dry Eye
Completed·CCenter for Ophthalmic and Vision Research, LLC·Phase 4·NCT04835623·50 enrolled
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00101829·12 enrolled
Pilot Study of Thalidomide to Treat Sjogren's Syndrome
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001599·28 enrolled
Levocarnitine for Dry Eye in Sjogren's Syndrome
Completed·VVanderbilt University Medical Center·Phase 2·NCT03953703·15 enrolled
Probiotics as a Prophylaxis to Prevent Clinical Manifestations of Oral Candidosis in Patients With Sjogren's Syndrome
Completed·—·Phase 1/2·NCT03840538·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)